Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Bakris, George L., Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Rossing, Peter, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Joseph, Amer, Filippatos, Gerasimos·2020·New England Journal of Medicine
DOI 10.1056/nejmoa2025845

Cited by (2,893)

Items 301–400 of 2,893

  1. Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
    Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos F Fernandez-Hernando, Julie E. Goodwin · 2021 · Journal of the American Heart Association
  2. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes
    Yang Xu, Edouard L. Fu, Catherine M. Clase, Faizan Mazhar, Meg Jardine, Juan Jesús Carrero · 2021 · Kidney International
  3. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease
    Selvarajah, Viknesh, Robertson, Darren, Hansen, Lars, Jermutus, Lutz, Smith, Kirsten, Coggi, Angela, Sánchez, José, Chang, Yi-Ting, Yu, Hongtao, Parkinson, Joanna et al. · 2024 · Kidney International
  4. Lab-on-Eyeglasses to Monitor Kidneys and Strengthen Vulnerable Populations in Pandemics: Machine Learning in Predicting Serum Creatinine Using Tear Creatinine
    Surachate Kalasin, Pantawan Sangnuang, Werasak Surareungchai · 2021 · Analytical Chemistry
  5. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
    Johann K Bauersachs, Achim Lother · 2022 · Kidney International Supplements
  6. Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome
    Qing Hou, Shuyan Kan, Zhuang Wang, Jingsong Shi, Caihong Zeng, Dahai Yang, Song Jiang, Zhihong Liu · 2022 · Frontiers in Pharmacology
  7. SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
    Manuel Alfredo Podestà, Gianmarco Sabiu, Andrea Galassi, Paola Ciceri, Mario Gennaro Cozzolino · 2023 · Biomedicines
  8. Heart Failure in Patients with Chronic Kidney Disease
    Andrew V. Xanthopoulos, Adamantia Papamichail, Αlexandros Briasoulis, Konstantinos Loritis, Angeliki Bourazana, Dimitrios E. Magouliotis, Pantelis A. Sarafidis, Ioannis Stefanidis, John S. Skoularigis, Filippos K. Triposkiadis · 2023 · Journal of Clinical Medicine
  9. Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials
    Juan José García Sánchez, Juliette Catherine Thompson, David Alexander Scott, Rachel Evans, Naveen Rao, Elisabeth Sörstadius, Glen James, STEPHEN T. NOLAN, Eric T Wittbrodt, Alyshah Abdul Sultan et al. · 2021 · Advances in Therapy
  10. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria
    Janet B. McGill, Hermann G. Haller, Prabir Roy‐Chaudhury, Andrea Cherrington, Takashi Wada, Christoph Wanner, Linong Ji, Peter R Rossing · 2022 · BMJ Open Diabetes Research & Care
  11. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
    Peter R Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Luis Miguel Ruilope, Vivian Andrew Fonseca, Guillermo E. Umpierrez, Maria Luiza Caramori, Amer Joseph et al. · 2022 · Diabetes Obesity and Metabolism
  12. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation
    Michel Azizi, Felix Mahfoud, Michael A. Weber, Andrew S. P. Sharp, Roland Erich Schmieder, Philipp C. Lurz, Melvin David Lobo, Naomi D.L. Fisher, Joost Daemen, Michael J. Bloch et al. · 2022 · JAMA Cardiology
  13. The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes
    Rajiv Agarwal, Denis P. Fouque · 2022 · Nephrology Dialysis Transplantation
  14. Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists
    Amin Abedini, Andrea Sánchez-Navaro, Junnan Wu, Konstantin A. Klötzer, Ziyuan Ma, Bibek Poudel, Tomohito Doke, Michael S. Balzer, Julia Frederick, Hana Černecká et al. · 2023 · Journal of Clinical Investigation
  15. The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets
    Masanobu Takasu, Seiji Kishi, Hajime Nagasu, Kengo Kidokoro, Craig R. Brooks, Naoki Kashihara · 2024 · Kidney International Reports
  16. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease
    Brendon Lange Neuen, Emily K. Yeung, Janani Rangaswami, Muthiah Vaduganathan · 2024 · Nephrology Dialysis Transplantation
  17. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
    Katherine R. Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle Jenny Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner et al. · 2022 · Diabetes Care
  18. New drug approvals for 2021: Synthesis and clinical applications
    Shuo Yuan, Dan-Shu Wang, Hui Liu, Shengnan Zhang, Weiguang Yang, Meng Lv, Yuxue Zhou, Sai‐Yang Zhang, Jian Hua Song, Hong‐Min Liu · 2022 · European Journal of Medicinal Chemistry
  19. Management of type 2 diabetes in chronic kidney disease
    Jefferson L. Triozzi, L. Parker Gregg, Salim S. Virani, Sankar Dass Navaneethan · 2021 · BMJ Open Diabetes Research & Care
  20. Acute kidney injury in diabetes mellitus: Epidemiology, diagnostic, and therapeutic concepts
    Yuan Gui, Zachary Palanza, Haiyan Fu, Dong Feng Zhou · 2023 · The FASEB Journal
  21. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
    Hiddo J.L. Heerspink, Priya Vart, Niels Jongs, Brendon Lange Neuen, George L. Bakris, Brian Lee Claggett, Muthiah Vaduganathan, Finnian R. McCausland, Kieran F. Docherty, Pardeep S. Jhund et al. · 2023 · Diabetes Obesity and Metabolism
  22. Type 2 Diabetes
    Allison L. Crawford, Neda Laiteerapong · 2024 · Annals of Internal Medicine
  23. Therapy of IgA nephropathy: time for a paradigm change
    Jonathan Barratt, Richard A. Lafayette, Jürgen Floege · 2024 · Frontiers in Medicine
  24. Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
    Kosuke Sawami, Atsushi Tanaka, Koichi Node · 2024 · Cardiovascular Diabetology
  25. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Journal of Cardiac Failure
  26. Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
    Francesco Fioretti, Jeffrey Moore Testani, Maria Clarissa Tio, Bertram Pitt, Javed Butler · 2025 · Journal of the American College of Cardiology
  27. Consensus statement on the current pharmacological prevention and management of heart failure
    Andrew Paul Sindone, Carmine G. De Pasquale, John V. Amerena, C. Burdeniuk, Alicia Chan, Andrew J.S. Coats, David L. Hare, Peter Simon Macdonald, Aaron Leonid Sverdlov, John James Atherton · 2022 · The Medical Journal of Australia
  28. Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure
    Muthiah Vaduganathan, João Pedro Ferreira, Patrick Rossignol, Brendon Lange Neuen, Brian Lee Claggett, Marc Alan Pfeffer, John J.V. McMurray, Bertram Pitt, Faiez M. Zannad, Scott David Solomon · 2022 · European Journal of Heart Failure
  29. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
    Jorge Enrique Rojas-Rivera, Clara García-Carro, Ana I Ávila, Mar Espino, Mario Espinosa, Gema Maria Fernandez Juarez, Xavier Fulladosa, Marián Goicoechea, Manuel L. Macia, Enrique Morales et al. · 2023 · Clinical Kidney Journal
  30. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
    Xiaoling Luo, Jing Xu, Shoulian Zhou, Cheng Xue, Zewei Chen, Zhiguo Mao · 2023 · Clinical Journal of the American Society of Nephrology
  31. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
    Pantelis A. Sarafidis, Fotini Iatridi, Charles Joseph Ferro, Maria Eleni Alexandrou, Beatriz Fernández‐Fernández, Mehmet Kanbay, Francesca Mallamaci, Ionuţ Nistor, Patrick Rossignol, Christoph Wanner et al. · 2023 · Clinical Kidney Journal
  32. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
    Faiez M. Zannad, Arun Jayant Sanyal, Javed Butler, Veronica Miller, Stephen A. Harrison · 2024 · Nature Medicine
  33. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease
    Masatake Kobayashi, Bertram Pitt, João Pedro Ferreira, Patrick Rossignol, Nicolas Girerd, Faiez M. Zannad · 2025 · European Heart Journal
  34. MicroRNAs and their delivery in diabetic fibrosis
    Alexa Wonnacott, Laura Denby, Richard J. Coward, Donald J. Fraser, Timothy Bowen · 2021 · Advanced Drug Delivery Reviews
  35. Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials
    Peter Andrew McCullough, Alpesh Amin, Kevin M. Pantalone, Claudio Ronco · 2022 · Journal of the American Heart Association
  36. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
    Gerasimos S Filippatos, Stefan D. Anker, Phyllis August, Andrew J.S. Coats, James L. Januzzi, Boris Mankovsky, Peter R Rossing, Luis Miguel Ruilope, Bertram Pitt, Pantelis A. Sarafidis et al. · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
  37. Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
    Jack R. Jerome, Devy Deliyanti, Varaporn Suphapimol, Peter Kolkhof, Jennifer L. Wilkinson‐Berka · 2023 · International Journal of Molecular Sciences
  38. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression
    Hiddo J.L. Heerspink, Niels Jongs, Patrick Schloemer, Dustin J. Little, MEIKE DANIELA BRINKER, Christoph Tasto, Martin Karpefors, David Collins. Wheeler, George L. Bakris, Vlado Perkovic et al. · 2023 · Journal of the American Society of Nephrology
  39. Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance
    Thomas Ebert, Stefan D. Anker, Luis Miguel Ruilope, Paola Fioretto, Vivian Andrew Fonseca, Guillermo E. Umpierrez, Andreas L. Birkenfeld, Robert Lawatscheck, Charlie A. B. Scott, Katja Rohwedder et al. · 2023 · Diabetes Care
  40. Finerenone in Type 1 Diabetes and Chronic Kidney Disease
    Hiddo J.L. Heerspink, Andreas L. Birkenfeld, David Z.I. Cherney, Helen Martina Colhoun, Per‐Henrik Groop, Linong Ji, Niels Jongs, Chantal Mathieu, Richard E. Pratley, Sylvia E. Rosas et al. · 2026 · New England Journal of Medicine
  41. Acute Kidney Injury Leading to CKD is Associated with a Persistence of Metabolic Dysfunction and Hypertriglyceridemia
    Azadeh Harzandi, Sunjae Lee, Gholamreza Bidkhori, Sujit Kumar Saha, Bruce M. Hendry, Adil Mardinoğlu, Saeed Shoaie, Claire C. Sharpe · 2020 · iScience
  42. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun
    Pantelis A. Sarafidis, Alberto Ortíz, Charles Joseph Ferro, Jean‐Michel Halimi, Reinhold Hugo Kreutz, Francesca Mallamaci, Giuseppe Mancia, Christoph Wanner · 2021 · Journal of Hypertension
  43. Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
    Botros, Fady T., Gerstein, Hertzel C., Malik, Raleigh, Nicolay, Claudia, Hoover, Anastasia, Turfanda, Ibrahim, Colhoun, Helen M., Shaw, Jonathan E. · 2023 · Diabetes Care
  44. Slowing the Progression of Diabetic Kidney Disease
    Olivia Blazek, George L. Bakris · 2023 · Cells
  45. Effect of Avenciguat on Albuminuria in Patients with CKD
    Hiddo J.L. Heerspink, David Cherney, Abdul Halim Abdul Gafor, José Luis Górriz, Pablo E. Pérgola, Sydney C.W. Tang, Marc Desch, Hristo Iliev, Zhichao Sun, Dominik Steubl et al. · 2024 · Journal of the American Society of Nephrology
  46. Preventing diabetes complications
    Sophie Templer, Sarah Abdo, Tang Wong · 2024 · Internal Medicine Journal
  47. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe · 2021 · Frontiers in Pharmacology
  48. Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone
    Yujiro Maeoka, Xiao‐Tong Su, Wen‐Hui Wang, Xin‐Peng Duan, Avika Sharma, Na Li, Olivier Staub, James A. McCormick, David H. Ellison · 2022 · Hypertension
  49. Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century
    Radica Z. Alicic, Susanne B. Nicholas · 2022 · Mayo Clinic Proceedings
  50. Screening for chronic kidney disease: change of perspective and novel developments
    Dominique van Mil, Lyanne M. Kieneker, Hiddo J.L. Heerspink, Ron T. Gansevoort · 2024 · Current Opinion in Nephrology & Hypertension
  51. Unraveling Diabetic Kidney Disease: The Roles of Mitochondrial Dysfunction and Immunometabolism
    Phoom Narongkiatikhun, Ye Ji Choi, Hailey E Hampson, Jimmy Gotzamanis, Guanshi Zhang, Daniël H. van Raalte, Ian H. de Boer, Robert G. Nelson, Kalie L. Tommerdahl, Phillip J. McCown et al. · 2024 · Kidney International Reports
  52. Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives
    Jean Paule Joumaa, Angela Raffoul, Charbel Sarkis, Elizabeth Chatrieh, Sally Zaidan, Philippe Attieh, Frédéric Harb, Sami T. Azar, Hilda E. Ghadieh · 2025 · Journal of Clinical Medicine
  53. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
    Michael W. Walsh, David Collister, Martin Gallagher, Patrick Barry Mark, Janak de Zoysa, Jessica Tyrwhitt, Karthik Tennankore, Gilmar Reis, Denis Xavier, Wen J Liu et al. · 2025 · The Lancet
  54. The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury
    Nobuhiro Ayuzawa, Toshiro Fujita · 2021 · Journal of the American Society of Nephrology
  55. The Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers on Clinical Outcomes of Acute Kidney Disease Patients: A Systematic Review and Meta-Analysis
    Jui‐Yi Chen, I‐Jung Tsai, Heng‐Chih Pan, Hung‐Wei Liao, Javier A. Neyra, Vin‐Cent Wu, Shih‐Chieh Chueh · 2021 · Frontiers in Pharmacology
  56. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
    Edgar V. Lerma, Daniel J. Wilson · 2022 · Expert Review of Clinical Pharmacology
  57. Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: A Milestone Achieved
    Sarafidis, Pantelis, Papadopoulos, Christodoulos E., Kamperidis, Vasilios, Giannakoulas, George, Doumas, Michael · 2021 · Hypertension
  58. The mineralocorticoid receptor in chronic kidney disease
    Jonatan Barrera‐Chimal, Frédéric Jaisser, Hans‐Joachim Anders · 2021 · British Journal of Pharmacology
  59. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease
    Lerma, Edgar, White, William B., Bakris, George · 2023 · Postgraduate Medicine
  60. Finerenone in diabetic kidney disease: A systematic review and critical appraisal
    Awadhesh Kumar Singh, Ritu Singh, Ritu Singh, Anoop Misra · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  61. Diabetic kidney disease: from pathogenesis to multimodal therapy–current evidence and future directions
    Hui Zhang, Keding Wang, Hairui Zhao, Bowen Qin, Xiaojing Cai, Manyi Wu, Junhua Li, Jielian Wang · 2025 · Frontiers in Medicine
  62. The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization
    Raffaele Serra, Umberto Marcello Bracale, Nicola Ielapi, Luca DEL GUERCIO, Maria Donata Di Taranto, Maurizio Sodo, Ashour Michael, Teresa Faga, Egidio Bevacqua, Federica Jiritano et al. · 2021 · International Journal of General Medicine
  63. Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease
    Tatsufumi Oka, Y. Sakaguchi, Koki Hattori, Yuta Asahina, Sachio Kajimoto, Yohei Doi, J. Kaimori, Y. Isaka · 2022 · HYPERTENSION
  64. Effect of a Web-Based Management Guide on Risk Factors in Patients With Type 2 Diabetes and Diabetic Kidney Disease
    Juliana C.N. Chan, Yotsapon Thewjitcharoen, Thy Khue Nguyen, Alexander Tan, Yook Chin Chia, Chii‐Min Hwu, Jian Du, Thep Himathongkam, Kim-Leng Wong, Yun-Mi Choi et al. · 2022 · JAMA Network Open
  65. Management of traditional risk factors for the development and progression of chronic kidney disease
    Robin H. Lo, Yoko Narasaki, Sean Lei, Connie M. Rhee · 2023 · Clinical Kidney Journal
  66. Diagnostic and prognostic biomarkers for tubulointerstitial fibrosis
    Umut Rende, Anna Guller, Ewa Magdalena Goldys, Carol A. Pollock, Sonia Saad · 2023 · The Journal of Physiology
  67. Intersection Between Chronic Kidney Disease and Cardiovascular Disease
    Luke Joseph Laffin, George L. Bakris · 2021 · Current Cardiology Reports
  68. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
    Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Luis Miguel Ruilope, Pieter Gillard, Richard J. MacIsaac, Julio Wainstein et al. · 2022 · Diabetes Care
  69. Diabetic kidney disease treatment: new perspectives
    Lili Tong, Sharon G. Adler · 2022 · Kidney Research and Clinical Practice
  70. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
    Shunichiro Tsukamoto, Ryutaro Morita, Takayuki Yamada, Shingo Urate, Kengo Azushima, Kazushi Uneda, Ryu Kobayashi, Tomohiko Kanaoka, Hiromichi Wakui, Kouichi Tamura · 2022 · Diabetes Research and Clinical Practice
  71. Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
    Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle · 2021 · Advances in Chronic Kidney Disease
  72. Diabetes-Related Microvascular Complications – A Practical Approach
    Basem M. Mishriky, Doyle M. Cummings, James R. Powell · 2022 · Primary Care Clinics in Office Practice
  73. Early Identification of CKD—A Scoping Review of the Global Populations
    Ikechi Gareth Okpechi, Fergus John Caskey, Abduzhappar Gaipov, Elliot Koranteng Tannor, Jean Jacques Noubiap, Emmanuel Effa, Udeme E. Ekrikpo, Laura N. Hamonic, Gloria Enow Ashuntantang, Aminu Kasarawa Bello et al. · 2022 · Kidney International Reports
  74. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis
    Reid H. Whitlock, Silvia J. Leon, Hazel Manacsa, Nicole Askin, Claudio Rigatto, Samuel Fatoba, Youssef M.K. Farag, Navdeep Tangri · 2023 · Nephrology Dialysis Transplantation
  75. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
    Rajiv Agarwal, Bertram Pitt, Peter R Rossing, Stefan D. Anker, Gerasimos S Filippatos, Luis Miguel Ruilope, Csaba Pal Kovesdy, Katherine R. Tuttle, Muthiah Vaduganathan, Christoph Wanner et al. · 2023 · JAMA Cardiology
  76. Genetic and epigenetic background of diabetic kidney disease
    Niina Sandholm, Emma H. Dahlström, Per‐Henrik Groop · 2023 · Frontiers in Endocrinology
  77. A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
    Shuhui Zhai, Baisheng Ma, Weiwei Chen, Qini Zhao · 2024 · Frontiers in Cardiovascular Medicine
  78. Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases
    Michel Azizi, Julien Mallart-Riancho, Laurence Amar · 2024 · The Journal of Clinical Endocrinology & Metabolism
  79. Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects
    Pia Clara Pafundi, Carlo Garofalo, Raffaele Galiero, Silvio Borrelli, Alfredo Caturano, Luca Rinaldi, Michele Provenzano, Teresa Salvatore, Luca De Nicola, Roberto Minutolo et al. · 2021 · Diagnostics
  80. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
    Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori · 2021 · Clinical and Experimental Nephrology
  81. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    Mingzhu Zhang, Wujisiguleng Bao, Qiyan Zheng, Ya‐Hui Wang, Luying Sun · 2022 · Frontiers in Pharmacology
  82. The 2019 and 2021 International Workshops on Alport Syndrome
    Sergio Daga, Jie Ding, Constantinos C. Deltas et al. · 2022 · European Journal of Human Genetics
  83. A study of the molecular mechanism of quercetin and dasatinib combination as senolytic in alleviating age‐related and kidney diseases
    Khalid Saad Alharbi, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, Waleed Hassan Almalki, Imran Ahmed Kazmi, Fahad Ahmed Al-Abbasi, Sami Ibrahim Alzarea, Hafiz Antar Makeen, Mohammed Albratty · 2022 · Journal of Food Biochemistry
  84. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
    Christian W. Mende, Rohan Samarakoon, Paul J. Higgins · 2023 · American Journal of Nephrology
  85. Novel mechanisms of salt-sensitive hypertension
    Liffert Vogt, Francine Z. Marques, Toshiro Fujita, Ewout Jasper Hoorn, A.H. Jan Danser · 2023 · Kidney International
  86. Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
    Frederik Flindt Kreiner, Philip Andreas Schytz, Hiddo J.L. Heerspink, Bernt Johan von Scholten, Thomas Idorn · 2023 · Biomedicines
  87. Updates on New Therapies for Patients with CKD
    Tushar Tarun, Sai Nikhila Ghanta, Vincz Ong, Rajshekhar A. Kore, Lakshmi Menon, Csaba Pal Kovesdy, Jawahar Lal Mehta, Nishank Jain · 2023 · Kidney International Reports
  88. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy
    Adam Ioannou, Yousuf Razvi, Aldostefano Porcari, Muhammad Umaid Rauf, Ana Martinez–Naharro, Lucia Venneri, Salsabeel Kazi, Ali Pasyar, Carina Mouritsen Luxhøj, Aviva Petrie et al. · 2024 · JAMA Cardiology
  89. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
    Lucia Del Vecchio, Angelo Beretta, Carlo Jovane, Silvia Peiti, Simonetta Genovesi · 2021 · Drugs
  90. Nuclear receptors in renal health and disease
    Zhi‐Lin Luan, Cong Zhang, Wenhua Ming, Yingzhi Huang, Youfei Guan, Xiaoyan Zhang · 2022 · EBioMedicine
  91. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
    Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, Georgios S. Germanidis · 2022 · Pharmacological Research
  92. Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort
    Carol A. Pollock, Glen James, Juan José García Sánchez, Juan Jesús Carrero, Matthew Arnold, Carolyn S.P. Lam, Hungta Chen, STEPHEN T. NOLAN, Roberto Pecoits‐Filho, David Collins. Wheeler · 2022 · Clinical Kidney Journal
  93. Therapeutic Targets for Diabetic Kidney Disease: Proteome-Wide Mendelian Randomization and Colocalization Analyses
    Wei Zhang, Leilei Ma, Qianyi Zhou, Tianjiao Gu, Xiaotian Zhang, Haitao Xing · 2024 · Diabetes
  94. Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
    Stefan Richard Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, Friedrich Schulze, Lisa Cronin, Arne Wenz, Katherine R. Tuttle, Samy Hadjadj, Peter R Rossing · 2024 · Diabetes Obesity and Metabolism
  95. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
    Shweta Bansal, Maria Eugênia Fernandes Canziani, Rita Birne, Stefan D. Anker, George L. Bakris, Gerasimos S Filippatos, Peter R Rossing, Luis Miguel Ruilope, Alfredo E. Farjat, Peter Kolkhof et al. · 2024 · BMJ Open
  96. Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT
    Brett Wesley Sperry, Marla B. Sultan, Balarama K. Gundapaneni, Sandi See Tai, Ronald M. Witteles · 2024 · JACC CardioOncology
  97. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study
    Kazuomi Kario, Hiroyuki Ohbayashi, Masami Hashimoto et al. · 2024 · Hypertension Research
  98. The dual role of lipids in chronic kidney disease: Pathogenic culprits and therapeutic allies
    Elena Giardini, Dean Moore, Denise M. Sadlier, Catherine Godson, Eoin Patrick Brennan · 2024 · Atherosclerosis
  99. Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
    João Pedro Ferreira, Bertram Pitt, Faiez M. Zannad · 2024 · Circulation Heart Failure
  100. Metabolic dysfunction–associated kidney disease: pathogenesis and clinical manifestations
    Anip Bansal, Michel Chonchol · 2025 · Kidney International